Cargando…
Molecular stratification within triple-negative breast cancer subtypes
Triple-negative breast cancer (TNBC) has been subdivided into six distinct subgroups: basal-like 1 (BL1), basal-like 2 (BL2), mesenchymal (M), mesenchymal stem–like (MSL), immunomodulatory (IM), and luminal androgen receptor (LAR). We recently identified a subgroup of TNBC with loss of the tumor sup...
Autores principales: | Wang, Dong-Yu, Jiang, Zhe, Ben-David, Yaacov, Woodgett, James R., Zacksenhaus, Eldad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911070/ https://www.ncbi.nlm.nih.gov/pubmed/31836816 http://dx.doi.org/10.1038/s41598-019-55710-w |
Ejemplares similares
-
A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling
por: Wang, Dong-Yu, et al.
Publicado: (2019) -
Stratifying the stratifiers of triple negative breast cancer
por: Wang, Dong-Yu, et al.
Publicado: (2020) -
CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer
por: Shrestha, Mariusz, et al.
Publicado: (2023) -
Inhibition of eEF2K synergizes with glutaminase inhibitors or 4EBP1 depletion to suppress growth of triple-negative breast cancer cells
por: Ju, YoungJun, et al.
Publicado: (2021) -
Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer
por: Liu, Jeff C., et al.
Publicado: (2018)